It needs to crest $85 or better to get me interested in reducing my share inventory. A drop to $57 will trigger an addition of 12% to share count.
I'd like to see it crest $72 and maintain that price right now.
Best wishes,
OAG
Buy from the Scared; Sell to the Greedy.....
Recent CRSP News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2026 01:44:04 PM
- CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones • GlobeNewswire Inc. • 01/12/2026 01:36:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2026 10:35:03 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/06/2026 10:11:41 PM
- CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/05/2026 01:30:00 PM
- Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize • PR Newswire (US) • 01/02/2026 06:29:00 PM
- Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize • PR Newswire (Canada) • 01/02/2026 06:29:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/23/2025 10:33:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/22/2025 10:35:04 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/22/2025 09:20:24 PM
- CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies • GlobeNewswire Inc. • 12/22/2025 01:30:00 PM
- From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes • GlobeNewswire Inc. • 12/16/2025 05:00:04 PM
- Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions • PR Newswire (US) • 12/09/2025 04:57:00 PM
- Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions • PR Newswire (Canada) • 12/09/2025 04:57:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/10/2025 01:15:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 01:10:33 PM
- CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results • GlobeNewswire Inc. • 11/10/2025 01:00:00 PM
- CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering • GlobeNewswire Inc. • 11/08/2025 02:56:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/04/2025 09:48:34 PM
- Intellia stock plunges after halting gene therapy trials over safety issue • IH Market News • 10/27/2025 02:35:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/20/2025 09:35:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/15/2025 09:35:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/15/2025 09:35:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/15/2025 08:18:42 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/15/2025 08:10:44 PM
Rainmaker Worldwide Inc. Announces Settlement Agreement Resolving Legacy Debt Obligation • RAKR • Jan 15, 2026 10:35 AM
Xalles Holdings Announces Management Changes • XALL • Jan 12, 2026 8:46 AM
One World Products Enters 2026 Positioned for Disciplined Growth as Isiah Enterprises • OWPC • Jan 8, 2026 12:22 PM
ConnectM Acquires 40% of Sun Solar, Strengthening Balance Sheet and Expanding National Solar & Storage Footprint in Multi-Billion Dollar U.S. Residential Solar & Storage Market • CNTM • Jan 7, 2026 9:00 AM
EVTV Executes Transformational AZIO AI Acquisition Framework at $3.00 Per Share • EVTV • Jan 6, 2026 7:00 AM
Fifty1 Labs, Inc. Clarifies Status Regarding Previously Announced Collaboration with LUNR Aerospace • FITY • Jan 5, 2026 1:00 PM
